FiercePharma

Bracco Diagnostics Receives U.S. FDA Approval for Expanded Labeling of MultiHance® (gadobenate dimeglumine) Injection in Magnetic Resonance Angiography

Bracco Diagnostics Inc., the US-based company of the Bracco Group – one of the world's leading companies in the diagnostic imaging business – today announced that the U.S. Food and Drug Administration ...
Monthly Prescribing Reference

FDA Expands Pediatric Age Range for MultiHance Contrast Agent

The FDA's approval was supported by data specifically gathered in patients aged Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved an expanded age range for ...
Monthly Prescribing Reference

MultiHance Approved for Magnetic Resonance Angiography

MULTIHANCE (gadobenate dimeglumine) 529mg/mL solution for IV injection by Bracco Diagnostics Bracco Diagnostics announced that the FDA has approved the use of MultiHance (gadobenate dimeglumine) ...
Reuters

Bracco Diagnostics Receives FDA Approval For Use Of Multihance Injection In Patients Younger Than 2

The Federal Aviation Administration said on Friday it is planning additional helicopter route changes near Ronald Reagan Washington National Airport after the January 29 mid-air collision of an ...
MedPage Today

FDA Orders Black Box Warning for Gadolinium-Based Contrast Agents

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ROCKVILLE, Md., ...